McGill, iSAEC Partner on TB Drug Reactions | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) –Montreal's McGill University will partner with the International Serious Adverse Events Consortium (iSAEC) to enable studies of the genetic basis of adverse reactions to Tuberculosis treatment.

The iSAEC's International Drug Induced Liver Injury Consortium (IDILIC) currently is recruiting patients with serious liver injuries from drugs and McGill is serving as the coordinating center for an international randomized trial for the treatment of latent TB.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.